Forte Biosciences, Inc.

NASDAQ:FBRX

Biotechnology

Healthcare
$76.99 +1.71%

+$0.30 today

Market cap
$1.58B
Beta
2.87
P/E (TTM)
-42.1
EPS (TTM)
-$0.43
52W Low $9.10High $35.80

Volume 0.00M

Average 0.30M

FBRX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Forte Biosciences, Inc.NASDAQ: FBRX

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How FBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
FBRX Competitors
Revenue for FBRX and competitors
Company Period LTM YoY 3-year CAGR
ALECAlector, Inc.LTM Mar 2026$18.42M USD-79.2%-46.0%
FATEFate Therapeutics, Inc.LTM Mar 2026$6.32M USD-52.6%-59.0%
CRDFCardiff Oncology, Inc.LTM Mar 2026$525K USD-10.7%+15.4%
FBRXForte Biosciences, Inc.LTM Mar 2026$0 USD——
PEPGPepGen Inc.LTM Mar 2026$0 USD——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD——
NKTXNkarta, Inc.LTM Mar 2026$0 USD——
MOLNMolecular Partners AGLTM Mar 2026CHF 0 CHF-100.0%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$0 USD——
ACTUActuate Therapeutics IncLTM Mar 2026$0 USD——
Peer median (excluding FBRX) —-65.9%-46.0%

Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue36K09K39K64K
Gross Profit(36K)0(9K)(39K)(64K)
Gross Margin—————
Research & Development13.85M5.59M21.86M21.19M58.25M
Selling, General & Admin7.63M8.3M10.62M15.37M12.41M
Operating Expenses21.49M13.9M32.48M36.56M70.66M
Depreciation & Amortization36K36K9K39K64K
EBITDA(21.67M)(13.84M)(31.47M)(35.44M)(68.27M)
EBITDA Margin—————
Operating Income(21.49M)(13.9M)(32.49M)(36.6M)(70.66M)
Operating Margin—————
Interest Income001.12M1.31M2.72M
Interest Expense00000
Other Income / Expenses(222K)17K1.01M1.12M2.32M
Income Before Tax(21.71M)(13.88M)(31.48M)(35.48M)(68.34M)
Pre-Tax Margin—————
Income Tax Expense00001.04M
Net Income(21.71M)(13.86M)(31.48M)(35.48M)(69.38M)
Net Margin—————
EPS (Basic)(38.85)(19.96)(24.92)(12.17)(4.71)
EPS (Diluted)(38.85)(19.96)(24.92)(12.17)(4.71)
Weighted Avg Shares558.71K695.34K1.26M2.92M147.18M
Weighted Avg Shares (Diluted)558.71K695.34K1.26M2.92M147.18M

Forte Biosciences, Inc.

NASDAQ:FBRX

Intrinsic Alpha fair value

Locked

Current Price

$76.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.